Finerenone: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Finerenone appears in the FDA drug-label database. Marketed as Kerendia.
- Drug class
- Nonsteroidal Mineralocorticoid-Receptor Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Mineralocorticoid Receptor Antagonists (as stated on the FDA label)
FDA-approved use
Kerendia is indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%. Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). ( 1 ) cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% ( 1 )
Phase breakdown
Conditions being studied
Recruiting trials involving Finerenone
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
- A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
- Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism
- Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
- The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
- Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
Common questions
Is Finerenone FDA-approved?
Yes, marketed as Kerendia.
How many recruiting trials involve Finerenone?
10 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.